Royalty Option Sample Clauses

Royalty Option. Owner grants to MAX the exclusive right to purchase a portion of the Royalty. The Royalty purchase price shall be One Million Dollars ($1,000,000.00) for one percent (1%) of the Royalty. XXX xxx exercise the option to purchase the Royalty at any time within six (6) months after a positive feasibility study for the Royalty Property is issued. If MA.X does not timely exercise the option to purchase the Royalty, it shall be deemed to have irrevocably terminated and waived the option to purchase the Royalty. If MAX timely exercises the option to purchase the Royalty, the parties shall diligently attempt to close the purchase of the Royalty within thirty (30) days following MAX RESOURCES' delivery of notice of its election. MAX shall deliver the purchase price for the Royalty in cash or by wire transfer directed to an account designated by Owner and Owner shall execute and deliver to MAX a conveyance of the portion of the Royalty purchase. On closing of the option to purchase the Royalty, MAX shall acquire and own the portion of the Royalty subject to the option and Owner shall retain the Royalty of two percent (2%). No Rental Payments paid under the Agreement and no Advance Payments or Royalty payments paid under this Deed shall apply to the Royalty purchase price.
Sample 1
AutoNDA by SimpleDocs
Royalty Option. 3.1 Kodiak is hereby granted the sole and exclusive option to purchase up to one-third of the Royalty (i.e. 1.0%) from the Optionors for $2,000,000, such option to be exercisable until 5:00 p.m. (local time in Vancouver, B.C.) on the second anniversary of the date of exercise of the Option by notice in writing accompanied by payment of the purchase price therefor.
Sample 1
Royalty Option. For the thirty (30) day period immediately succeeding the earlier of the approval date of the BLA or the approval date of the Intrathecal BLA, Children’s shall have the option (the “Royalty Option”), but only if it owns at the date of exercise of such option, fifty percent (50%) or more of the Shares issued in the name of Children’s pursuant to this Agreement or, after the Internal Restructuring, at least fifty percent (50%) or more of the AveXis Shares issued in the name of Children’s, to sell all, but not less than all, of its Shares or its AveXis Shares, as applicable, to Licensee or AveXis (as defined in Section 7.4), as applicable, at a price per share equal to two (2) times the price per share of common stock sold by Licensee or AveXis, as applicable, in its Series A Financing, with such consideration paid in four (4) equal quarterly installments, commencing on **** and continuing on ****. Furthermore, for the thirty (30) day period immediately succeeding the earlier of the approval date of the BLA or the approval date of the Intrathecal BLA, notwithstanding anything to the contrary in this Agreement, OSU shall also have the option (the “OSU Royalty Option”), but only if it owns at the date of exercise of such option, fifty percent (50%) or more of the OSU Shares or, after the Internal Restructuring, at least fifty percent (50%) or more of the OSU AveXis Shares (as defined in Section 7.4), to sell all, but not less than all, of its OSU Shares, or its OSU AveXis Shares, as applicable, to Licensee or AveXis, as applicable, at a price per share equal to two (2) times the price per share of common stock sold by Licensee or AveXis, as applicable, in its Series A Financing, with such consideration paid in four (4) equal quarterly installments, commencing on **** and continuing on ****.
Sample 1
Royalty Option. Owner grants to Triband the exclusive right to purchase one-half (1/2) of the Royalty representing two percent (2%) of the Net Smelter Returns. The Royalty Price for the Royalty Option shall be One Million Dollars ($1,000,000.00). The Royalty Option shall be exercisable by Triband at any time within six (6) months after Triband's receipt of all approvals, consents, licenses and permits required for the production of Minerals from the Property and the commencement of development of a commercial mine on the Property. If Triband exercises the Royalty Option, it shall deliver notice of its election and the parties shall close the purchase of the Royalty in the same manner provided for Triband's exercise and closing of the Option prescribed in Section 6.1.1 through 6.1.5. If Triband exercises the Royalty Option, the Royalty percentage rate described in Section 5.3 shall be reduced to two percent (2%), unless before or concurrently with the closing of the Royalty Option Triband exercises the Option, in which case the Royalty shall terminate.
Sample 1
Royalty Option. In the event Newmont elects not to exercise the Venture Option described in Section 9 below, or elects to exercise the Venture Option but thereafter elects to not complete its Earn-In Expenditures (as described below) and provided that AuEx has not previously exercised the Buy-Out Option under Section 6 above, (i) Newmont shall transfer to AuEx all its interest in the Newmont Property by Quit Claim Deed and Assignment in the form of Exhibit E hereto, (ii) AuEx shall convey to Newmont a net smelter return royalty on production from the Property by executing and delivering to Newmont a royalty deed in the form of Exhibit F hereto (“Royalty Deed”), (iii) AuEx would pay $1,000,000 to Newmont in cash by certified check or wire transfer and (iv) this Agreement shall terminate, if it has not previously terminated under Section 9(a)(vi) below. This provision shall survive any termination of this Agreement under Section 9(a)(vi) of this Agreement, until Newmont completes its Earn-In Expenditures. The Quit Claim Deed and Assignment shall be recorded in the Pershing County records before the Royalty Deed is recorded.
Sample 1
Royalty Option. In the event that VERTEX does not exercise the Bulk Supply Option or the Joint Venture Option with respect to a particular Second Opportunity Candidate or Subsequent Drug Candidate, NOVARTIS shall undertake production using its own manufacturing resources or Third Party manufacturers pursuant to the license granted in Section 2.1 of this Agreement, and shall have access to all information generated by VERTEX relating to the supply of that Bulk Drug Substance. In such event, NOVARTIS shall pay the following royalties to VERTEX (subject to the provisions of Section 6.3 providing for royalty reduction in certain instances), in lieu of the royalties set forth in Section 6.3 hereof, on Net Sales of a Drug Product containing the foregoing Second Opportunity or Subsequent Drug Candidate: [****************************************************************** ******************************************************************* *********************************************]
Sample 1
Royalty Option. Subject to all of the terms and conditions of this Agreement and for the consideration described in this Agreement, Rubicon grants to Claimstaker the option to purchase an absolute two percent (2%) of the three percent (3%)
Sample 1
AutoNDA by SimpleDocs
Royalty Option. Subject to all of the terms and conditions of this Deed and for the consideration described in this Deed, Grantor grants to Grantee the option to purchase an absolute two percent (2%) of the three percent (3%)
Sample 1

Related to Royalty Option

  • Know-How Royalty Notwithstanding the provisions of Section 5.4.1(a), in countries where the sale of Product by Merck or its Related Parties would not infringe a Valid Patent Claim, Merck shall pay royalty rates that shall be set at [***] of the applicable royalty rate determined according to Section 5.4.1(a). Such royalties shall be calculated after first calculating royalties under Section 5.4.1(a).

  • Earned Royalty In addition to the annual license maintenance fee, ***** will pay Stanford earned royalties (Y%) on Net Sales as follows:

  • Royalty Payment For all leased substances that are sold during a particular month, Lessee shall pay royalties to Lessor on or before the end of the next succeeding month. Royalty payments shall be accompanied by a verified statement, in a form approved by Lessor, stating the amount of leased substances sold, the gross proceeds accruing to Lessee, and any other information reasonably required by Lessor to verify production and disposition of the leased substances or leased substances products. Delinquent royalties may be subject to late fees and penalties in accordance with Lessor’s Rules.

  • Sublicense Consideration Company shall pay to JHU a percentage of consideration received for sublicenses under this Agreement as set forth in Exhibit A. This sublicense consideration shall be due, without the need for invoice from JHU, within forty-five (45) days of Company’s receipt. Such consideration shall mean consideration of any kind received by the Company or AFFILIATED COMPANIES from a SUBLICENSEE(S) for the grant of a sublicense under this Agreement, such as upfront fees or milestone fees, running royalties and including any premium paid by the SUBLICENSEE(S) over Fair Market Value for stock of the Company or an AFFILIATED COMPANY in consideration for such sublicense. However, not included in such sublicense consideration are amounts paid to the Company or an AFFILIATED COMPANY by the SUBLICENSEE(S) for product development, research work, clinical studies and regulatory approvals performed by or for the Company or AFFILIATED COMPANIES (including third parties on their behalf), each pursuant to a specific agreement including a performance plan and commensurate budget. The term “Fair Market Value” shall mean the average price that the stock in question is publicly trading at for twenty (20) days prior to the announcement of its purchase by the SUBLICENSEE(S) or if the stock is not publicly traded, the greater of (a) the value of such stock as determined by the most recent private financing through a financial investor (an entity whose sole interest in the Company or AFFILIATED COMPANY is financial) of the Company or AFFILIATED COMPANY that issued the shares, or (b) the value of such stock as determined by the most recent appraisal conducted by an independent appraiser regularly engaged in the business of valuing businesses of the nature of Company or AFFILIATED COMPANY, as applicable. In the event of a sublicense under both this Agreement and any other license agreement between Company and JHU, the sublicensing consideration payable to JHU under this Agreement and such other license agreement(s) shall be capped such that the aggregate amount payable to JHU shall not exceed the percentage set forth in Exhibit A of all sublicensing consideration.

  • Running Royalties Company shall pay to JHU a running royalty as set forth in Exhibit A, for each LICENSED PRODUCT(S) sold, and for each LICENSED SERVICE(S) provided, by Company or AFFILIATED COMPANIES, based on NET SALES and NET SERVICE REVENUES for the term of this Agreement. Such payments shall be made quarterly. All non-US taxes related to LICENSED PRODUCT(S) or LICENSED SERVICE(S) sold under this Agreement shall be paid by Company and shall not be deducted from royalty or other payments due to JHU. In order to insure JHU the full royalty payments contemplated hereunder, Company agrees that in the event any LICENSED PRODUCT(S) shall be sold to an AFFILIATED COMPANY or SUBLICENSEE(S) or to a corporation, firm or association with which Company shall have any agreement, understanding or arrangement with respect to consideration (such as, among other things, an option to purchase stock or actual stock ownership, or an arrangement involving division of profits or special rebates or allowances) the royalties to be paid hereunder for such LICENSED PRODUCT(S) shall be based upon the greater of: 1) the net selling price (per NET SALES) at which the purchaser of LICENSED PRODUCT(S) resells such product to the end user, 2) the NET SERVICE REVENUES received from using the LICENSED PRODUCT(S) in providing a service, or 3) the net selling price (per NET SALES) of LICENSED PRODUCT(S) paid by the purchaser. No multiple royalties shall be due or payable because any LICENSED PRODUCT(S) or LICENSED SERVICE(S) is covered by more than one claim of the PATENT RIGHTS or by claims of both the PATENT RIGHTS under this Agreement and “PATENT RIGHTS” under any other license agreement between Company and JHU. The royalty shall not be cumulative based on the number of patents or claims covering a product or service, but rather shall be capped at the rate set forth in Exhibit A.

  • Production Royalty The amount of the Royalty shall be determined at the end of each month after the Effective Date. The Royalty shall be determined monthly on the basis such that payments will be determined as of and paid within thirty (30) days after the last day of each month during which Lessee produces any Geothermal Resources. The Royalty rates shall be determined as follows:

  • One Royalty No more than one royalty payment shall be due with respect to a sale of a particular Licensed Product. No multiple royalties shall be payable because any Licensed Product, or its manufacture, sale or use is covered by more than one Valid Claim.

  • Second Option If Tenant exercises the First Option, Landlord grants Tenant an additional option (the "Second Option") to extend the term of the Lease for one (1) additional term of five (5) years (the "Second Option Term"). The Second Option applies only to the Premises and is on the following conditions:

  • Earned Royalties Subject to of Article 7 hereof, Licensee shall pay to Licensor for the rights granted hereunder a sum equal to one and [*****] of the Net Invoice Value of Trademarked Products Sold by Licensee (the "Royalties"). The Royalties shall be remitted in accordance with Section 7.4 of this Agreement. 6.2

  • Sublicense Revenue In the event Licensee or an Affiliate of Licensee sublicenses under Section 2.2, Licensee shall pay CareFusion **THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION.** of any Sublicense Revenues resulting from sublicense agreements executed by Licensee.

Time is Money Join Law Insider Premium to draft better contracts faster.